Editing Pemetrexed (section)

{{Short description|Chemical compound}}
{{Use dmy dates|date=November 2022}}
{{Infobox drug
| Verifiedfields = changed
| verifiedrevid = 464197624
| image = Pemetrexed.svg
| image2 = Pemetrexed ball-and-stick.png

<!--Clinical data-->
| tradename = Alimta, Pemfexy, Ciambra, others
| Drugs.com = {{drugs.com|monograph|pemetrexed-disodium}}
| DailyMedID = Pemetrexed
| pregnancy_AU = D
| routes_of_administration = [[Intravenous therapy|Intravenous]]
| ATC_prefix = L01
| ATC_suffix = BA04
| ATC_supplemental =

| legal_AU = S4
| legal_AU_comment = <ref>{{cite web | title=Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017 | website=Therapeutic Goods Administration (TGA) | date=21 June 2022 | url=https://www.tga.gov.au/resources/publication/publications/prescription-medicines-registration-new-generic-medicines-and-biosimilar-medicines-2017 | access-date=30 March 2024}}</ref>
| legal_UK = POM
| legal_US = Rx-only
| legal_US_comment = <ref name="Alimta FDA label" /><ref name="Pemfexy FDA label">{{cite web | title=Pemfexy- pemetrexed injection | website=DailyMed | date=20 January 2022 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2308f4e8-21c8-49c1-a5b8-deb8610bac6a | access-date=20 May 2022 | archive-date=21 May 2022 | archive-url=https://web.archive.org/web/20220521021818/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2308f4e8-21c8-49c1-a5b8-deb8610bac6a | url-status=live }}</ref>
| legal_EU = Rx-only
| legal_EU_comment = <ref name="Alimta EPAR">{{cite web | title=Alimta EPAR | website=European Medicines Agency | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/alimta | access-date=14 October 2022 | archive-date=18 January 2021 | archive-url=https://web.archive.org/web/20210118214202/https://www.ema.europa.eu/en/medicines/human/EPAR/alimta | url-status=live }}</ref><ref>{{cite web | title=Pemetrexed Baxter: Pending EC decision | website=European Medicines Agency | date=14 October 2022 | url=https://www.ema.europa.eu/en/medicines/human/summaries-opinion/pemetrexed-baxter | access-date=14 October 2022 | archive-date=14 October 2022 | archive-url=https://web.archive.org/web/20221014175806/https://www.ema.europa.eu/en/medicines/human/summaries-opinion/pemetrexed-baxter | url-status=live }}</ref>

<!--Pharmacokinetic data-->
| bioavailability = NA
| protein_bound = 81%
| metabolism = Negligible
| elimination_half-life = 3.5 hours
| excretion = [[Kidney]]

<!--Identifiers-->
| index2_label = as salt
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 137281-23-3
| PubChem = 135410875
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00642
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 393879
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 04Q9AIZ7NO
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07472
| KEGG2_Ref = {{keggcite|correct|kegg}}
| KEGG2 = D06503
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 225072

<!--Chemical data-->
| IUPAC_name = (2''S'')-2-<nowiki/>{[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-''d'']pyrimidin-5-yl)ethyl]benzoyl]amino}pentanedioic acid
| C=20 | H=21 | N=5 | O=6 
| smiles = Nc3nc2[nH]cc(CCc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)c2c(=O)[nH]3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C20H21N5O6/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29)/t13-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = WBXPDJSOTKVWSJ-ZDUSSCGKSA-N
}}

'''Pemetrexed''', sold under the brand name '''Alimta''' among others, is a [[chemotherapy]] medication for the treatment of [[pleural]] [[mesothelioma]] and [[non-small cell lung cancer]] (NSCLC).<ref name="Alimta FDA label" />

It is available as a [[generic medication]].<ref>{{cite web | title=2022 First Generic Drug Approvals | website=U.S. [[Food and Drug Administration]] (FDA) | date=3 March 2023 | url=https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/2022-first-generic-drug-approvals | archive-url=https://web.archive.org/web/20230630003602/https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/2022-first-generic-drug-approvals | archive-date=30 June 2023 | url-status=live | access-date=30 June 2023}}</ref><ref>{{cite web | title=Competitive Generic Therapy Approvals | website=U.S. [[Food and Drug Administration]] (FDA) | date=29 June 2023 | url=https://www.fda.gov/drugs/generic-drugs/competitive-generic-therapy-approvals | access-date=29 June 2023 | archive-date=29 June 2023 | archive-url=https://web.archive.org/web/20230629233651/https://www.fda.gov/drugs/generic-drugs/competitive-generic-therapy-approvals | url-status=live }}</ref>